Danaher Clocks Q1 Sales Jump Of 12%, COVID-19-Related Restrictions In China To Impact Q2 Sales

Loading...
Loading...
  • Danaher Corp DHR logged Q1 FY22 adjusted EPS of $2.76, up 9.5% Y/Y, surpassing the estimate of $2.66.
  • Sales increased 12% to $7.7 billion, with 12% non-GAAP core and 8.0% non-GAAP base business core revenue growth, beating the $7.54 billion estimate.
  • Operating cash flow reached $2 billion. Non-GAAP free cash flow reached $1.7 billion.
  • The gross margin declined to 61.2% from 62% a year ago, and the operating margin also compressed from 29.1% to $28.3%.
  • Rainer Blair, President & CEO, stated, "We had a good start to the year with results exceeding our initial expectations. Our team successfully navigated a dynamic environment to deliver double digit core revenue growth, approximately 10% adjusted earnings per share growth and $2.0 billion of operating cash flow, despite difficult prior year comparisons."
  • Outlook: Danaher expects Q2 FY22 non-GAAP base business core revenue growth in mid-single-digit percent, including an approximately 200 to 300 basis point headwind from the COVID-19 related shutdowns in China.
  • For FY22, the company reaffirms non-GAAP base business core revenue growth outlook in high-single-digit percentages.
  • Price Action: DHR shares closed 0.11% higher at $280.8 during after-hours trading on Wednesday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...